CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts.

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty reagents in the life science research, diagnostic, and drug discovery space, announced the recent acquisition of Salt Lake City-based Echelon Biosciences, a trusted supplier of critical materials, notably lipid-based excipients, to its growing portfolio. This acquisition serves as the second investment under VION Biosciences LLC (“VION Biosciences”), Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.